Relevant bibliographies by topics / ZD6474

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Conference papers

Academic literature on the topic 'ZD6474'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'ZD6474.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "ZD6474"

1

Heymach, J. V., B. E. Johnson, D. Prager, et al. "A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results." Journal of Clinical Oncology 24, no. 18_suppl (2006): 7016. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7016.

Full text
Abstract:
7016 Background: ZD6474, a once-daily oral agent, targets key signaling pathways in cancer by inhibiting VEGF, EGF and RET receptor tyrosine kinases. ZD6474 in combination with docetaxel (Doc) was assessed in patients (pts) with refractory non-small-cell lung cancer (NSCLC). Methods: Pts eligible for this randomized, double-blind study had locally advanced or metastatic (stage IIIB/IV) NSCLC after failure of 1st-line platinum-based chemotherapy. The primary objective was to determine whether once-daily oral ZD6474 (100 or 300 mg) + Doc (75 mg/m2 i.v. infusion every 21 days) prolonged progressi
APA, Harvard, Vancouver, ISO, and other styles
2

Natale, R. B., D. Bodkin, R. Govindan, et al. "ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial." Journal of Clinical Oncology 24, no. 18_suppl (2006): 7000. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7000.

Full text
Abstract:
7000 Background: ZD6474 is a once-daily oral agent that targets key signaling pathways in cancer by inhibiting VEGF, EGF and RET receptor tyrosine kinase activity. The efficacy and safety of ZD6474 was compared with that of gefitinib, an EGFR tyrosine kinase inhibitor. Methods: Patients with locally advanced or metastatic (stage IIIB/IV) non-small-cell lung cancer (NSCLC), after failure of 1st-line ± 2nd-line platinum-based chemotherapy because of toxicity or tumor progression, received daily oral doses of ZD6474 (300 mg) or gefitinib (250 mg) until disease progression or evidence of toxicity
APA, Harvard, Vancouver, ISO, and other styles
3

Carlomagno, Francesca, Teresa Guida, Suresh Anaganti, et al. "Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474." Endocrine-Related Cancer 16, no. 1 (2009): 233–41. http://dx.doi.org/10.1677/erc-08-0213.

Full text
Abstract:
ZD6474 (vandetanib, Zactima, Astra Zeneca) is an anilinoquinazoline used to target the receptor tyrosine kinase RET in familial and sporadic thyroid carcinoma (IC50: 100 nM). The aim of this study was to identify molecular determinants of RET sensitivity to ZD6474. Here, we show that mutation of RET tyrosine 806 to cysteine (Y806C) induced RET kinase resistance to ZD6474 (IC50: 933 nM). Y806 maps close to the gate-keeper position at the RET kinase nucleotide-binding pocket. Although tyrosine 806 is a RET auto-phosphorylation site, its substitution to phenylalanine (Y806F) did not markedly affe
APA, Harvard, Vancouver, ISO, and other styles
4

Wells, S., Y. N. You, V. Lakhani, et al. "A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer." Journal of Clinical Oncology 24, no. 18_suppl (2006): 5533. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.5533.

Full text
Abstract:
5533 Background: Medullary thyroid carcinoma (MTC) is the most common cause of death in patients with hereditary syndromes caused by specific mutations in the RET protooncogene. RET activation is the oncogenic event, which results in intrinsic RET receptor tyrosine kinase activity, but other pathways, such as VEGFR- and EGFR-dependent signaling, also participate in tumor growth and development. ZD6474 is a once-daily oral agent that selectively targets RET, VEGFR and EGFR tyrosine kinases. The clinical activity of ZD6474 was evaluated in patients with hereditary MTC. Methods: In this open-labe
APA, Harvard, Vancouver, ISO, and other styles
5

Morelli, M. P., T. Cascone, T. Troiani, et al. "Antitumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases." Journal of Clinical Oncology 24, no. 18_suppl (2006): 13170. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.13170.

Full text
Abstract:
13170 Background: The epidermal growth factor receptor (EGFR) autocrine pathway plays an important role in cancer cell growth. Vascular endothelial growth factor A (VEGF-A) is a key regulator of tumor-induced endothelial cell proliferation and vascular permeability. ZD6474 (ZACTIMA™) is an orally available, small molecule inhibitor of VEGF receptor-2 (VEGFR-2), EGFR and RET tyrosine kinase activity. We investigated the activity of ZD6474 in combination with cetuximab, an anti-EGFR blocking monoclonal antibody, to determine the antitumor activity of EGFR blockade through the combined use of two
APA, Harvard, Vancouver, ISO, and other styles
6

Troiani, T., O. Lockerbie, M. Morrow, F. Ciardiello, and S. G. Eckhardt. "ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases, blocks VEGF-C-induced activation of VEGFR-3 and cell proliferation in human colon cancer cell lines." Journal of Clinical Oncology 24, no. 18_suppl (2006): 13171. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.13171.

Full text
Abstract:
13171 Background: Vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR-1, -2 and -3) have a key role in activation and proliferation of endothelial cells, with expression of VEGFR-3 largely restricted to lymphatic endothelial cells. Although high expression of VEGFR-3 and its specific ligands, VEGF-C and VEGF-D, has been associated with an increased incidence of lymph node metastasis and a poor prognosis in different human malignancies, little is known about the role of this signaling pathway in tumor cells. This study investigated VEGFR-3 and its specific ligands in human colon canc
APA, Harvard, Vancouver, ISO, and other styles
7

Nakagawa, K., K. Kiura, T. Shinkai, et al. "A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC." Journal of Clinical Oncology 24, no. 18_suppl (2006): 7067. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7067.

Full text
Abstract:
7067 Background: ZD6474 is a once-daily oral therapy that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptor (VEGFR)-dependent tumor angiogenesis, and epidermal growth factor receptor (EGFR)- and RET-dependent cancer cell proliferation and survival. ZD6474 was evaluated as monotherapy in an ongoing randomized, double-blind, parallel-group, Phase IIa, dose-finding, multicenter study in Japan. Methods: Patients with locally advanced or metastatic (stage IIIB/IV) or recurrent non-small-cell lung cancer (NSCLC), after failure of one or tw
APA, Harvard, Vancouver, ISO, and other styles
8

Kovacs, Michael J., Donna E. Reece, Deborah Marcellus, et al. "A Phase II Study of ZD6474, a Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed Multiple Myeloma (MM)." Blood 104, no. 11 (2004): 3464. http://dx.doi.org/10.1182/blood.v104.11.3464.3464.

Full text
Abstract:
Abstract ZD6474 targets angiogenesis by inhibiting VEGFR TK and also affects EGFR signaling by inhibiting EGFR TK activity. This oral agent showed dose-related tumor growth inhibition in a broad range of in vivo xenograft models. In Phase I studies, drug- and dose-related adverse events included rash, diarrhea, hypertension, and asymptomatic QT/QTc prolongation. Four patients with NSCLC included in the phase I studies exhibited partial responses. Because MM is a disease in which angiogenesis is postulated to be a relevant target for therapy, we conducted a phase II trial of ZD6474 100 mg p.o.
APA, Harvard, Vancouver, ISO, and other styles
9

Heymach, J. V. "ZD6474 – clinical experience to date." British Journal of Cancer 92, S1 (2005): S14—S20. http://dx.doi.org/10.1038/sj.bjc.6602604.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nair, Binoj C., and Ratna K. Vadlamudi. "ZD6474 coerces breast cancer for an apoptotic journey." Cancer Biology & Therapy 9, no. 8 (2010): 604–6. http://dx.doi.org/10.4161/cbt.9.8.11318.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "ZD6474"

1

Sandström, Maria. "Experimental therapies of malignant glioma : with emphasis on angiogenesis inhibition." Doctoral thesis, Umeå universitet, Institutionen för strålningsvetenskaper, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1955.

Full text
Abstract:
Malignant glioma consists of a group of diseases where the localisation and the nature of the disease makes treatment an extreme challenge. Two important biological features of malignant glioma cells are their infiltrative growth and their ability to induce angiogenesis. Glioma cells migrate extensively behind the blood-brain barrier and infiltrate the surrounding brain making radical treatment with surgery and radiotherapy almost impossible. The aims of this thesis were to investigate factors of importance for glioma cell migration and angiogenesis and to evaluate if an anti-angiogenesis appr
APA, Harvard, Vancouver, ISO, and other styles
2

Wiegand, Ulrich. "Antiangiogenetische Therapie des humanen Pankreaskarzinoms durch ZD6474, ein neuartiger Inhibitor des vaskulären endothelialen Wachstumsfaktorrezeptor VEGF-R2 (KDR/FLK-1) Tyrosinkinase, nach orthotoper Implantation in die Nacktmaus." Diss., lmu, 2009. http://nbn-resolving.de/urn:nbn:de:bvb:19-98926.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ma, Hong [Verfasser]. "Target therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in tumor-bearing nude mice / vorgelegt von Hong Ma." 2008. http://d-nb.info/996162283/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wiegand, Ulrich [Verfasser]. "Antiangiogenetische Therapie des humanen Pankreaskarzinoms durch ZD6474, ein neuartiger Inhibitor des vaskulären endothelialen Wachstumsfaktorrezeptor VEGF-R2 (KDR/FLK-1) Tyrosinkinase, nach orthotoper Implantation in die Nacktmaus / vorgelegt von Ulrich Wiegand." 2009. http://d-nb.info/993679471/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Yu-hsin, and 陳郁心. "Francis Poulenc Petites Voix''s Music Analysis and Interpretation." Thesis, 2007. http://ndltd.ncl.edu.tw/handle/zd6x7x.

Full text
Abstract:
碩士<br>國立中山大學<br>音樂學系研究所<br>95<br>Francis Poulenc ( 1899-1963 ) is one of the most important French composers in the early 20th -century. Influenced by Neo-classicism, Poulenc developed his own personal musical language which is light, humorous, and sagacious. He wrote in many different musical genres during his life, including ballet, opera, piano, vocal, choral, and chamber music. In 1936, after his good friend Pierre-Octave Ferroud’ sudden death in a car accident and religious experience in Rocamadour, Poulenc started to compose choral music, including Petites Voix. Petites Voix, completed i
APA, Harvard, Vancouver, ISO, and other styles
6

Hong, Wei-Huang, and 洪唯晃. "A Study of Teachers’ Perception and Acceptance of Electronic Textbooks at Junior High School in Kaohsiung City." Thesis, 2017. http://ndltd.ncl.edu.tw/handle/zd6a54.

Full text
Abstract:
碩士<br>義守大學<br>資訊管理學系<br>105<br>This study is based on the technology acceptance model that Davis (1989) proposed. The primary purpose of this study is to explore junior high school teachers&apos;&apos; behavior pattern of using electronic textbooks; mainly the relationships among the external variables, perceived usefulness, perceived ease of use, and intention to use.This study used random sampling questionnaire survey method targeted at junior high school teachers in Kaoshiung City. Statistic methods included average, standard deviation, t-test, ANOVA and pearson product-moment correlation c
APA, Harvard, Vancouver, ISO, and other styles
7

Mason, William Lowell. "Feeling Machines: Immersion, Expression, and Technological Embodiment in Electroacoustic Music of the French Spectral School." Thesis, 2019. https://doi.org/10.7916/d8-k4nh-zd64.

Full text
Abstract:
This dissertation considers the music and technical practice of composers affiliated with French spectralism, including Hugues Dufourt, Gérard Grisey, Tristan Murail, Jean-Claude Risset, and Kaija Saariaho. They regularly described their work, which was attuned to the transformative experiences that technologies of electronic sound production and reproduction could inspire in listeners, using metaphoric appeals to construction: to designing new sounds or exploring new illusory aural phenomena. To navigate a nascent but fast-expanding world of electronic and computer music, the spectralists app
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "ZD6474"

1

Kim, Yoo-shin, and Brian E. O'Neill. "Abstract A18: Modified ZD6474 (Vandetanib) derivatives with VEGFR2 and non-peptide integrin antagonist (IA) slows tumor growth." In Abstracts: AACR Special Conference: Tumor Angiogenesis and Vascular Normalization: Bench to Bedside to Biomarkers; March 5-8, 2015; Orlando, FL. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-8514.tumang15-a18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Chen, Yunyun, Maria Gule, Robert Lemos, et al. "Abstract 1401: Evaluation of vandetanib (ZD6474) and radiation therapy in an orthotopic xenograft model of anaplastic thyroid carcinoma." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'ZD6474' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography